Purpose Conventional radiotherapy (C-RT) treatment schedules for patients with prostate
cancer typically require 40 to 45 treatments that take place from> 8 to 9 weeks. Preclinical …

Due to its low fractionation sensitivity, also known as “alpha/beta ratio,” in relation to its
surrounding organs at risk, prostate cancer is predestined for hypofractionated radiation …

Purpose Use of stereotactic body radiation therapy (SBRT) is increasing in patients with
localized prostate cancer, but concerns about early and late gastrointestinal (GI) and …

Purpose Dose escalation improves localized prostate cancer disease control, and
moderately hypofractionated external beam radiation is noninferior to conventional …

Purpose A constant relative biological effectiveness (RBE) of 1.1 is currently used in proton
radiation therapy to account for the increased biological effectiveness compared to photon …

With over a decade׳ s worth of clinical experience to guide stereotactic body radiotherapy
(SBRT) for the treatment of clinically localized prostate cancer (PCa), sufficient data exist for …

Simple summary Stereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with
the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk …

Purpose Although high-level evidence supports moderately hypofractionated radiation
therapy for definitive prostate treatment, there is less evidence for its use in the …

Postoperative external beam radiation therapy (EBRT) is a validated treatment option in the
adjuvant setting for prostate cancer patients with aggressive pathological features following …

For a patient suffering from non-metastatic prostate cancer, the individualized
recommendation of radiotherapy has to be the fruit of a multidisciplinary approach in the …